Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVASTIM: NiNA System vs Tolterodine for Overactive Bladder
NCT07780786Phase 3Not yet recruiting
- Sponsor
- NinaMED
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in overactive bladder (OAB) (2 arms), sponsored by NinaMED. Primary endpoint: Number of urgency urinary incontinence episodes per day at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT07780786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07780786.